The FDA rejected sotagliflozin for type 1 diabetes and CKD. Lexicon will focus on LX9211 for diabetic neuropathic pain, with phase 2b data expected in 2025. Sotagliflozin's regulatory journey has ...

The latest findings on sotagliflozin and eGFR slope in patients with diabetes and chronic kidney disease further indicates the dual SGLT 1 and 2 inhibitor provides a degree of kidney protection ...

The US Food and Drug Administration (FDA) declined to approve sotagliflozin (Zynquista) as an adjunct to insulin therapy for people with type 1 diabetes (T1D) and chronic kidney disease (CKD).

“Although this was not our desired outcome for sotagliflozin in this indication, we remain steadfast in our commitment to advancing our clinical pipeline, including our near-term focus on LX9211 ...

20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding ...

Regulators in the US and Europe are to review Sanofi/Lexicon’s sotagliflozin in type 1 diabetes, a potential blockbuster pill. The French firm is trying to rebuild sales following loss of patent ...

Update 5.33 PM EST, Oct. 31: Adds information about sotagliflozin, stock halt Update 9.49 AM EST, Nov. 01: Adds latest share price move and CEO’s remarks. More on Lexicon Pharmaceuticals ...